Cargando…
Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis
BACKGROUND: COVID-19 has infected over 35 million people worldwide and led to over 1 million deaths. Several risk factors that increase COVID-19 severity have emerged, including age and a history of cardiovascular disease, hypertension, or kidney disease. However, a number of outstanding questions p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238636/ https://www.ncbi.nlm.nih.gov/pubmed/34221254 http://dx.doi.org/10.1016/j.csbj.2021.06.038 |
_version_ | 1783714941256073216 |
---|---|
author | Lee, Abby C. Li, Wei Tse Apostol, Lauren Ma, Jiayan Taub, Pam R. Chang, Eric Y. Rajasekaran, Mahadevan Ongkeko, Weg M. |
author_facet | Lee, Abby C. Li, Wei Tse Apostol, Lauren Ma, Jiayan Taub, Pam R. Chang, Eric Y. Rajasekaran, Mahadevan Ongkeko, Weg M. |
author_sort | Lee, Abby C. |
collection | PubMed |
description | BACKGROUND: COVID-19 has infected over 35 million people worldwide and led to over 1 million deaths. Several risk factors that increase COVID-19 severity have emerged, including age and a history of cardiovascular disease, hypertension, or kidney disease. However, a number of outstanding questions persist, including whether the above comorbidities correlate with increased mortality from COVID-19 or whether age is a significant confounding variable that accounts for the observed relationship between COVID-19 severity and other comorbidities. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of studies documenting COVID-19 patients with hypertension, cardiovascular disease, cerebrovascular disease, or chronic kidney disease. We classified COVID-19 cases into severe/non-severe or deceased/surviving and calculated the odds ratio (OR) for each of the four comorbidities in these cohorts. 36 studies, comprising 22,573 patients, are included in our meta-analysis. We found that hypertension is the most prevalent comorbidity in deceased COVID-19 patients (55.4%; CI: 49.4–61.3%), followed by cardiovascular disease (30.7%; CI: 22.6–38.8%), cerebrovascular disease (13.4%; CI: 9.12–19.2%), then chronic kidney disease (9.05%; CI: 5.57–15.0%). The risk of death is also significantly higher for patients with these comorbidities, with the greatest risk factor being chronic kidney disease (OR: 8.86; CI: 5.27–14.89), followed by cardiovascular disease (OR: 6.87; CI: 5.56–8.50), hypertension (OR: 4.87; CI: 4.19–5.66), and cerebrovascular disease (OR: 4.28; CI: 2.86–6.41). These risks are significantly higher than previously reported, while correlations between comorbidities and COVID-19 severity are similar to previously reported figures. Using meta-regression analysis with age as a moderating variable, we observed that age contributes to the observed risks but does not explain them fully. CONCLUSIONS: In this meta-analysis, we observed that cardiovascular, cerebrovascular, and kidney-related comorbidities in COVID-19 significantly contributes to greater risk of mortality and increased disease severity. We also demonstrated that age may not be a confounder to these associations. |
format | Online Article Text |
id | pubmed-8238636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Research Network of Computational and Structural Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-82386362021-06-29 Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis Lee, Abby C. Li, Wei Tse Apostol, Lauren Ma, Jiayan Taub, Pam R. Chang, Eric Y. Rajasekaran, Mahadevan Ongkeko, Weg M. Comput Struct Biotechnol J Research Article BACKGROUND: COVID-19 has infected over 35 million people worldwide and led to over 1 million deaths. Several risk factors that increase COVID-19 severity have emerged, including age and a history of cardiovascular disease, hypertension, or kidney disease. However, a number of outstanding questions persist, including whether the above comorbidities correlate with increased mortality from COVID-19 or whether age is a significant confounding variable that accounts for the observed relationship between COVID-19 severity and other comorbidities. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of studies documenting COVID-19 patients with hypertension, cardiovascular disease, cerebrovascular disease, or chronic kidney disease. We classified COVID-19 cases into severe/non-severe or deceased/surviving and calculated the odds ratio (OR) for each of the four comorbidities in these cohorts. 36 studies, comprising 22,573 patients, are included in our meta-analysis. We found that hypertension is the most prevalent comorbidity in deceased COVID-19 patients (55.4%; CI: 49.4–61.3%), followed by cardiovascular disease (30.7%; CI: 22.6–38.8%), cerebrovascular disease (13.4%; CI: 9.12–19.2%), then chronic kidney disease (9.05%; CI: 5.57–15.0%). The risk of death is also significantly higher for patients with these comorbidities, with the greatest risk factor being chronic kidney disease (OR: 8.86; CI: 5.27–14.89), followed by cardiovascular disease (OR: 6.87; CI: 5.56–8.50), hypertension (OR: 4.87; CI: 4.19–5.66), and cerebrovascular disease (OR: 4.28; CI: 2.86–6.41). These risks are significantly higher than previously reported, while correlations between comorbidities and COVID-19 severity are similar to previously reported figures. Using meta-regression analysis with age as a moderating variable, we observed that age contributes to the observed risks but does not explain them fully. CONCLUSIONS: In this meta-analysis, we observed that cardiovascular, cerebrovascular, and kidney-related comorbidities in COVID-19 significantly contributes to greater risk of mortality and increased disease severity. We also demonstrated that age may not be a confounder to these associations. Research Network of Computational and Structural Biotechnology 2021-06-29 /pmc/articles/PMC8238636/ /pubmed/34221254 http://dx.doi.org/10.1016/j.csbj.2021.06.038 Text en © 2021 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Lee, Abby C. Li, Wei Tse Apostol, Lauren Ma, Jiayan Taub, Pam R. Chang, Eric Y. Rajasekaran, Mahadevan Ongkeko, Weg M. Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis |
title | Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis |
title_full | Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis |
title_fullStr | Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis |
title_full_unstemmed | Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis |
title_short | Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis |
title_sort | cardiovascular, cerebrovascular, and renal co-morbidities in covid-19 patients: a systematic-review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238636/ https://www.ncbi.nlm.nih.gov/pubmed/34221254 http://dx.doi.org/10.1016/j.csbj.2021.06.038 |
work_keys_str_mv | AT leeabbyc cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT liweitse cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT apostollauren cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT majiayan cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT taubpamr cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT changericy cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT rajasekaranmahadevan cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis AT ongkekowegm cardiovascularcerebrovascularandrenalcomorbiditiesincovid19patientsasystematicreviewandmetaanalysis |